1441results about "Dispersion delivery" patented technology

The invention discloses a macrophage-targeting inhalable nano material, a preparation method thereof and application of the inhalable nano material in treatment of sepsis myocarditis, and belongs to the technical field of medicines. The nano-material is a nano-liposome, the nano-liposome comprises a mannose modified nano-liposome microsphere, and the mannose modified nano-liposome microsphere comprises a liposome skeleton shell layer, a drug and a targeting layer; the liposome skeleton shell layer comprises soybean lecithin and cholesterol; the medicine comprises quercetin and TPPU (Thermoplastic Polyurethane); and the targeting layer is formed by connecting mannose modified DSPE-PEG2000 to the outer surface of the liposome skeleton shell layer. The nano material can accurately target macrophages at a cardiac inflammation part, has a multi-target-point synergistic effect, is more convenient and faster in administration, remarkably improves the safety and comprehensively improves the treatment effect.

The present invention provides, among other things, improved pharmaceutical compositions comprising codon-optimized mRNA encoding a peptide or polypeptide encapsulated in a lipid nanoparticle comprising one or more of the cationic lipids that are particularly effective for pulmonary delivery.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating meniere disease membrane hydrolost and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: rhizoma alismatis, rhizoma atractylodis macrocephalae, poria cocos, gastrodia elata, ginger processed pinellia, pericarpium citri reticulatae and fresh ginger. The traditional Chinese medicine composition disclosed by the invention is small in dosage and special in effect, and dialectical compatibility is performed according to the phlegm-dampness theory of traditional Chinese medicine, combined with the pathological basis of the meniere disease and based on the treatment rules of transforming fluid retention, inducing diuresis, tonifying spleen and calming liver, so that the aim of treating both symptoms and root causes is achieved. Animal experiments prove that the traditional Chinese medicine composition can obviously relieve the cochlear hydrops degree of a rat with membranous hydrolost.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

Methods to edit genes by administering a chimeric nuclease to a cell or organism without the use of a viral vector.

The present invention relates to a composition comprising a compound represented by general formula (1), a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and a surfactant. [wherein R1, P1, R2, P3, P4, R5, P6, R10, P10 and P11 are C1 to C6 alkyl or the like; R3 and P9 are hydrogen or the like; R7 is phenethyl optionally substituted by halogen or the like; R8 forms a 4-to 7-membered saturated heterocyclic ring together with a carbon atom bonded to P8 and R8 and a nitrogen atom bonded to P8; R9 forms a 3- to 8-membered alicyclic ring together with Q9 and a carbon atom bonded to R9 and Q9; and R11 is di-C1 to C6 alkylaminocarbonyl or the like].

The invention provides application of qi-blood foundation strengthening oral liquid in preparation of a medicine for building body and resisting aging, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by adopting the modes of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood not only has the effective component content, but also has the health-care effect. The oral liquid for consolidating qi and blood has the effects of improving the activity of superoxide dismutase of red blood cells and reducing the content of lipofuscin in tissues, can improve the exercise tolerance of rats, and has the effects of resisting aging and building the body.

The invention includes methods of preventing or treating acute lung injury using a MAP3K2 / MAP3K3 inhibitor. The invention further comprises compositions, and kits comprising compositions useful within the invention.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

The invention provides application of qi and blood strengthening oral liquid in preparation of a medicine for improving hyperlipidemia, and belongs to the technical field of medicine preparations. According to the invention, the mass ratio relationship among the components and the preparation method thereof are researched, and especially in the preparation process, the traditional Chinese medicine components are extracted by means of high-pressure steam heating, vacuum concentration and the like under different pressures in batches and stages, so that the obtained oral liquid for consolidating qi and blood is high in content of effective components, and has a good effect on consolidating qi and blood. The oral liquid for consolidating qi and blood can significantly improve hyperlipidemia, and has potential clinical application value.

Introduced here is a face mask system having a mask enclosure that contains, or otherwise directly supports, an automated liquid-droplet dispensing mechanism (ADM) for humidification. In operation, the enclosure and ADM are compact and lightweight so that when worn by a user can be supported entirely by the user's head and neck. The enclosure can be comprised of one or more layers of breathable fabric adapted to flexibly conform to the face of a user when worn and form a cavity that is adjacent to the user's nostrils and mouth. The ADM can be comprised of a reservoir in which liquid is stored, a respiratory cycle detector, a timer and controller, and a droplet dispenser that controllably dispenses droplets of the liquid from the reservoir into the cavity for inhalation by the user.

The invention discloses a targeted slow-release curcumin compound with an auxiliary liver protection function and a preparation method thereof.The preparation method comprises the steps that whey protein isolate is heated under the acidic condition to prepare whey protein isolate fibers, and then the whey protein isolate fibers are compounded with kappa-carrageenan; adjusting the mixed system to be alkaline by adopting a pH migration method, adding a curcumin alkaline solution, fully dissolving the curcumin alkaline solution, and combining the curcumin alkaline solution with the whey protein isolate fiber-kappa-carrageenan composite system; and adjusting the pH value of the system back to be neutral to obtain the high-load amorphous curcumin solution and the solid preparation. The whey fiber and the kappa-carrageenan are self-assembled in the pH circulation process to form a composite carrier, curcumin is converted into an amorphous state from a crystalline state, the solubility of curcumin is remarkably improved, the loading capacity is greatly improved to 70% at most, the heat stability, oxidation resistance and biological accessibility of curcumin are improved, targeted slow release of curcumin can be achieved, and the curcumin-targeted slow release preparation has a good application prospect. The positioning release performance of the curcumin in the intestinal tract part is improved, and the application form of the curcumin in liver protection function products is expanded.

A system and method for enhanced aerosol drug delivery during high flow nasal cannula (HFNC) therapy. The system comprises a breath enhanced jet nebulizer (BEJN) connected to a high flow medical breathing gas supply supplying breathing gas to the BEJN at flow rates of 5 L / min to 60 L / min, a nebulization gas supply, a drug infusion device that supplies a drug solution to the nebulizer for the delivery of nebulized drug to a patient. All the breathing gas and nebulized drug solution delivered to the patient passes through the BEJN. The rate of drug delivery increases with increases in the flow rate of the medical breathing gas supply and increases in infusion pump flow rates. The drug solution infusion rate is between 5 mL / hour and 50 mL / hour. This system and method enable efficient aerosol drug delivery to patients during HFNC therapy for prolonged periods, improving treatment outcomes.

The present disclosure relates to the fields of chemistry and medicine, more particularly to processes for making 4-(2-chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]-5-methyl-N-prop-2-ynyl-1,3-thiazol-2-amine (Compound 1), pharmaceutically acceptable salts, and crystalline forms thereof, for the treatment of congenital adrenal hyperplasia (CAH).

Provided are pharmaceutical formulations comprising a recombinant acid α-glucosidase, wherein the recombinant acid α-glucosidase is expressed in Chinese hamster ovary (CHO) cells and comprises an increased content of N-glycan units bearing one or two mannose-6-phosphate residues when compared to a content of N-glycan units bearing one or two mannose-6-phosphate residues of alglucosidase alfa; at least one buffer selected from the group consisting of a citrate, a phosphate and combinations thereof; and at least one excipient selected from the group consisting of mannitol, polysorbate 80, and combinations thereof, wherein the formulation has a pH of from about 5.0 to about 7.0. Also provided are methods of treating Pompe disease using these pharmaceutical formulations.

Oral pharmaceutical solution comprising a pharmaceutically acceptable salt of lisdexamfetamine, and a pharmaceutically acceptable aqueous carrier comprising a buffer and a cosolvent selected from the group consisting of a glycol, a polyol, and a mixture thereof, wherein the pH of the solution is from 5.5 to 9.0. The oral pharmaceutical solution presents excellent physicochemical stability, even under alkaline conditions.

Disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant. Particularly, disclosed is a pharmaceutical composition for inhalation comprising salbutamol or enantiomer or salt or ester thereof and a pharmaceutically acceptable green propellant HFA-152a and / or HFO-1234ze(E). Also disclosed processes of preparing such compositions.

The invention belongs to the technical field of biological medicine, and particularly relates to a reagent for improving ovarian development and a preparation method and application thereof. The reagent for improving ovarian development is prepared by mixing the following raw materials in parts by weight: 20-30 parts of N-acetylcysteine; 5 to 10 parts of tranexamic acid; 3 to 8 parts of creatine; and 3000 parts of water. According to the reagent, the mRNA expression of PKD1P6 and follicle stimulating hormone receptors (FSHR) in ovarian tissues is up-regulated, the activity and functions of cumulus granular cells are enhanced, and apoptosis of the cumulus granular cells is inhibited, so that the effects of effectively promoting follicle development and inhibiting the apoptosis of the cumulus granular cells are achieved.

The present invention relates to a method for subjecting a subject to an augmented reality (AR) or virtual reality (VR) experience. The method may comprise administering to the subject a composition comprising a cannabinoid compound. The method may comprise, subsequent to the administration of the composition comprising the cannabinoid compound, using an AR or VR device to subject the subject to an AR or VR experience. The method may comprise detecting a response of the subject to the AR or VR experience and the composition comprising the cannabinoid compound.

The disclosure provides for methods and compositions for treating respiratory obstructive diseases.

The present invention relates to formulations comprising dolutegravir or a pharmaceutically acceptable salt thereof, methods for making such formulations, and the use of such formulations in the treatment of HIV infection, particularly in the treatment of HIV infection in pediatric patients.

The invention relates to pharmaceutical compounds and pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds as inhibitors of the SMARCA2 protein and to their use in the treatment of SMARCA4 deficient cancers, e.g., SMARCA4 deficient non-small cell lung cancer (NSCLC).

An animal watering system is disclosed. The animal watering system comprises an activated water source and an animal watering station configured to receive activated water from the activated water source. The activated water source comprises a unipolar electrolytic cell configured to produce activated water containing a desired amount of hydrogen peroxide. A methane conversion system comprising an activated water source and a mixer for contacting activated water from the activated water source with a gas containing methane and with a source of Fe2+ ions is also disclosed.

The present invention relates to a method of treating a disease or disorder associated with the presence or formation of galectin-10 crystals, comprising administering to a subject in need thereof a therapeutically effective amount of a pharmaceutical composition comprising a Fab fragment that binds to galectin-10, wherein the composition is administered as an aerosol. Also included in the invention is a pharmaceutical composition comprising a Fab fragment that binds to galectin-10, and a nebulizer comprising the pharmaceutical composition. The pharmaceutical composition may be useful for treating a disease or disorder associated with the presence or formation of galectin-10 crystals, such as asthma or cystic fibrosis.

The present invention relates to a pharmaceutical liquid composition, wherein said liquid composition comprises at least one cooling agent comprising of a phenyl ring containing a polar side group at least one viscosity enhancing agent and at least one surfactant. The invention also relates to a method to produce such a pharmaceutical composition as well as a method of alleviating a symptom selected from the group consisting of cough, nasal congestion and sore throat in a subject comprising administering the composition according to any of preceding claims.

Disclosed herein are methods and compositions for involving a xanthine oxidase inhibitor that has enhanced solubility. The compositions described herein include a xanthine oxidase inhibitor combined with an organic base. The compositions can be used to treat a disease or medical condition that involves elevated uric acid levels.

The invention relates to the technical field of traditional Chinese medicines, and particularly discloses a traditional Chinese medicine compound preparation for treating slow transit type and mixed type constipation and a preparation method. The traditional Chinese medicine compound preparation is prepared from, by weight, 30 parts of fructus cannabis, 20 parts of radix salviae miltiorrhizae, 20 parts of raw oyster shells, 10 parts of vinegar schisandra chinensis, 5 parts of radix et rhizoma rhei, 20 parts of pericarpium citri reticulatae, 20 parts of radix paeoniae alba, 10 parts of radix bupleuri, 10 parts of radix scutellariae, 20 parts of fried fructus perillae, 20 parts of radix codonopsis, 6 parts of pericarpium zanthoxyli, 10 parts of honey-fried licorice roots, 40 parts of rhizoma atractylodis macrocephalae, 20 parts of poria cocos and 20 parts of radix rehmanniae. The formula is suitable for slow-transit constipation and slow-transit-dominated mixed constipation in western medicine classification, the problems that an existing formula only aims at single syndrome and is limited in curative effect are solved, the relapse rate of constipation is greatly reduced, meanwhile, accompanying symptoms such as abdominal distension and abdominal pain can be improved, and the defecation experience of patients is comprehensively improved.

The present disclosure is directed to method of treatment for treating or ameliorating various conditions pertaining such as bone marrow recovery (or blood cell production), fibrosis, inflammatory diseases, inhibition of cancer cell growth, propagation or malignancy, thrombocytopenia, wound healing, and conditions related to stem cells by the administration of BCN057, 512, or an analog thereof.

The present application belongs to the technical field of medicine preparation, and relates to application of a blood-nourishing oral liquid in preparation of medicine for improving blood oxygen saturation. The blood-nourishing oral liquid can improve blood oxygen saturation, improve hypoxemia, improve lung function, and has a preventive and / or therapeutic effect on lung injury, especially acute lung injury.